Ocean Biomedical Inc.
Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases in the United States. The company develops an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and … Read more
Ocean Biomedical Inc. (OCEA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of March 2025: 0.026x
Based on the latest financial reports, Ocean Biomedical Inc. (OCEA) has a cash flow conversion efficiency ratio of 0.026x as of March 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.52 Million) by net assets ($-97.62 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Ocean Biomedical Inc. - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Ocean Biomedical Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Ocean Biomedical Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ocean Biomedical Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Odessa Capital Ltd.
V:ALFA-P
|
N/A |
|
ORACLE - Dusseldorf Stock Exchang
DU:ORC
|
0.659x |
|
Omniq Corp
OTCQB:OMQS
|
0.049x |
|
CHECK PNT SFTWARE - Dusseldorf Stock Exchang
DU:CPW
|
0.088x |
|
PTC (PMTA.SG)
STU:PMTA
|
0.031x |
|
Medallion Resources Ltd
PINK:MLLOF
|
0.313x |
|
GOLDON RES LTD
F:6NR2
|
N/A |
|
TTGXF
OTCQB:TTGXF
|
-0.060x |
Annual Cash Flow Conversion Efficiency for Ocean Biomedical Inc. (2019–2024)
The table below shows the annual cash flow conversion efficiency of Ocean Biomedical Inc. from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-97.62 Million | $-4.18 Million | 0.043x | -58.78% |
| 2023-12-31 | $-90.76 Million | $-9.43 Million | 0.104x | +1549.90% |
| 2022-12-31 | $104.30 Million | $-747.30K | -0.007x | -104.53% |
| 2021-12-31 | $-6.66 Million | $-1.05 Million | 0.158x | +365.54% |
| 2020-12-31 | $-1.89 Million | $-64.00K | 0.034x | -87.69% |
| 2019-12-31 | $-232.00K | $-64.00K | 0.276x | -- |